A CAR-Macrophage (CAR-M) cell therapy model based on engineered macrophages was constructed to address the problem of interference in the immunosuppressive microenvironment in solid tumors. The model optimizes the design of signaling domains on the basis of traditional CAR structure, adopts nano-delivery and electro-transfer technology to achieve efficient transduction, and introduces a dual-target synergy module to enhance anti-tumor immune effects. In vitro experiments showed that the CD80 positivity rate of the CAR-M group reached 76.4%, and the IL-12 release was elevated to 312.7 pg/mL, which was significantly better than that of the control group. In the in vivo test, the survival rate at day 28 reached 66.7%, and the tumor volume was reduced by 64.4%, which significantly improved the response to treatment. The results indicate that the constructed CAR-M model has obvious advantages in functional activation and targeting ability, and has good potential for clinical translation.
Ziyang Gao (Tue,) studied this question.